Stakeholder Feedback on CADTH’s Proposed Revisions to its pan-Canadian Oncology Drug Review (pCODR) Clinician Input and Feedback Process

To submit your feedback, please complete this form and email it to [pcodrinfo@cadth.ca](mailto:pcodrinfo@cadth.ca%20) by **April 20, 2018 at 5:00 p.m. ET.**

|  |  |
| --- | --- |
| **Organization Providing Feedback:** |  |
| **Contact Persona:** |  |
| **Title:** |  |
| **Phone Number:** |  |
| **Email Address:** |  |

aCADTH may contact this person if comments require clarification.

| **I. Proposed Revisions to the pCODR Clinician Input Template** | |
| --- | --- |
| **#1** | In the proposed template, the following information would be provided:   * Funding request or submitter’s reimbursement ask (which may or may not be different than the Health Canada approved indication) * Citation of or reference to pivotal trial being submitted for review, and if available:   + URL to the ClinicalTrials.gov trial description   + URL to the trial publication (if publicly available) or to the abstract * Provincial funding status and funding algorithms of current treatments, if available.   Will this information assist you with providing context for your input? Is this too much information? Are there other sources of information that would be helpful? |
| **Feedback** |  |

|  |  |
| --- | --- |
| **I. Proposed Revisions to the pCODR Clinician Input Template** | |
| **#2** | CADTH posted a revised [Registered Clinician Input on a Drug Review template](https://cadth.ca/sites/default/files/pcodr/pCODR%27s%20Drug%20Review%20Process/pCODR%20Registered%20Clinician%20Input%20on%20a%20Drug%20Review.docx) on February 13, 2018. The questions on the template will remain on the proposed revisions.   * Are the instructions clear? * Are the questions clear? |
| **Feedback** |  |

|  |  |
| --- | --- |
| **I. Proposed Revisions to the pCODR Clinician Input Template** | |
| **#3** | As part of the input process and in addition to the templated questions for registered clinician input, there may be supplementary questions specific to the drug and indication for which input is being requested. Typically, these questions would relate to the applicability of clinical trial information in clinical practice and may include questions on potential public reimbursement criteria on existing treatments as well as the new drug.  Please provide any feedback you may have regarding the inclusion of targeted supplementary questions as part of the registered clinician input process. |
| **Feedback** |  |

|  |  |
| --- | --- |
| **II. Additional Stakeholders** | |
| **#4** | Oncology pharmacists and oncology nurses are part of a multi-disciplinary team involved in the care of a cancer patient. Often, oncology pharmacists and oncology nurses are members of a provincial drug advisory or therapeutics committee. CADTH is assessing the feasibility of extending the eligibility for input to oncology pharmacists and oncology nurses.  To be eligible, CADTH is proposing that oncology pharmacists and oncology nurses be registered with the pCODR program, be actively practising and be a member of a provincial cancer drug advisory or cancer therapeutics committee (e.g., the Cancer Care Ontario Breast Cancer Drug Advisory Committee), provide input as part of a joint submission with a registered clinician or a group of registered clinicians, and submit a declaration of conflict of interests (COI).  Are the eligibility criteria reasonable? |
| **Feedback** |  |